Novartis AG won U.S. approval for the Menveo meningococcal vaccine for use in children from two years of age, the company said today in a statement. Novartis received a “refuse to file letter” for use of the vaccine in infants and will resubmit the application, the company said.
EQUITIES: *Kaba Sells Door Automation to Nabtesco for SF220-240 Million
MARKETS: *The SMI lost 0.5 percent to close at 6,528.13 *The SPI fell 0.5 percent to close at 5,854.77 *Euro -- Franc at 1.2808 at 7:38 a.m. Zurich time
To contact the reporter on this story: Paul Verschuur at email@example.com
To contact the editor responsible for this story: Angela Cullen at firstname.lastname@example.org